Kaleido Biosciences, Inc. (KLDO): Price and Financial Metrics

Kaleido Biosciences, Inc. (KLDO): $0.00

0.00 (0.00%)

POWR Rating

Component Grades








Add KLDO to Watchlist
Sign Up

Industry: Biotech




#378 of 443

in industry

KLDO Price/Volume Stats

Current price $0.00 52-week high $0.03
Prev. close $0.00 52-week low $0.00
Day low $0.00 Volume 200
Day high $0.00 Avg. volume 4,569
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 4.26K

KLDO Stock Price Chart Interactive Chart >

Kaleido Biosciences, Inc. (KLDO) Company Bio

Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.

KLDO Latest News Stream

Event/Time News Detail
Loading, please wait...

KLDO Latest Social Stream

Loading social stream, please wait...

View Full KLDO Social Stream

Latest KLDO News From Around the Web

Below are the latest news stories about Kaleido Biosciences Inc that investors may wish to consider to help them evaluate KLDO as an investment opportunity.

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

Yahoo | February 24, 2022

Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

Yahoo | February 23, 2022

Is a Beat Likely for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Yahoo | February 22, 2022

Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Yahoo | February 17, 2022

Read More 'KLDO' Stories Here

KLDO Price Returns

1-mo 0.00%
3-mo N/A
6-mo N/A
1-year 0.00%
3-year 0.00%
5-year 0.00%
2023 0.00%
2022 -99.98%
2021 -73.74%
2020 81.27%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!